New York State Common Retirement Fund raised its holdings in Acceleron Pharma Inc. (NASDAQ:XLRN) by 11.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,300 shares of the biopharmaceutical company’s stock after purchasing an additional 3,599 shares during the period. New York State Common Retirement Fund owned 0.09% of Acceleron Pharma worth $1,042,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of XLRN. BlackRock Inc. grew its stake in Acceleron Pharma by 9.0% during the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after acquiring an additional 330,635 shares in the last quarter. Vanguard Group Inc. lifted its position in Acceleron Pharma by 9.1% during the first quarter. Vanguard Group Inc. now owns 1,912,335 shares of the biopharmaceutical company’s stock valued at $50,619,000 after purchasing an additional 158,714 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in Acceleron Pharma by 46.6% during the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after purchasing an additional 534,440 shares during the last quarter. Eagle Asset Management Inc. lifted its position in Acceleron Pharma by 6.6% during the second quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock valued at $38,189,000 after purchasing an additional 77,683 shares during the last quarter. Finally, State Street Corp lifted its position in Acceleron Pharma by 9.7% during the first quarter. State Street Corp now owns 1,034,625 shares of the biopharmaceutical company’s stock valued at $27,395,000 after purchasing an additional 91,451 shares during the last quarter. Hedge funds and other institutional investors own 77.46% of the company’s stock.

In related news, SVP John D. Quisel sold 5,113 shares of the stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $38.42, for a total transaction of $196,441.46. Following the transaction, the senior vice president now owns 57,918 shares of the company’s stock, valued at approximately $2,225,209.56. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Ravindra Kumar sold 13,065 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $35.41, for a total value of $462,631.65. Following the transaction, the senior vice president now directly owns 108,392 shares in the company, valued at approximately $3,838,160.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,578 shares of company stock worth $2,518,117. 3.90% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/new-york-state-common-retirement-fund-acquires-3599-shares-of-acceleron-pharma-inc-xlrn/1677425.html.

Shares of Acceleron Pharma Inc. (XLRN) opened at $37.04 on Friday.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. During the same period in the previous year, the company posted ($0.59) EPS. Acceleron Pharma’s revenue was down 3.1% on a year-over-year basis. sell-side analysts predict that Acceleron Pharma Inc. will post -2.71 EPS for the current year.

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Thursday. BidaskClub upgraded shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 6th. Zacks Investment Research upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Thursday, July 13th. Credit Suisse Group set a $35.00 price objective on shares of Acceleron Pharma and gave the stock a “buy” rating in a report on Saturday, August 5th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $40.00 price objective on shares of Acceleron Pharma in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $43.65.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc. (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.